Co-Diagnostics (CODX)
Market Price (4/22/2026): $1.64 | Market Cap: $3.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Co-Diagnostics (CODX)
Market Price (4/22/2026): $1.64Market Cap: $3.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -345% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -135%, 3Y Excs Rtn is -167% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -31 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5026% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -70% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 361% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4681%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4793% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1084% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1522% High stock price volatilityVol 12M is 2290% Key risksCODX key risks include [1] uncertain profitability and significant cash burn, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -345% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -135%, 3Y Excs Rtn is -167% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -31 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5026% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -70% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 361% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4681%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4793% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1084% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1522% |
| High stock price volatilityVol 12M is 2290% |
| Key risksCODX key risks include [1] uncertain profitability and significant cash burn, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant decline in financial performance for the full year 2025. Co-Diagnostics reported a substantial revenue drop of 84.6% to $0.6 million in 2025, compared to $3.9 million in 2024. Concurrently, the company's net loss increased to $46.9 million, or $35.25 per share, in 2025, up from a $37.6 million loss in 2024. This deterioration was primarily driven by lower grant revenue and an $18.9 million non-cash impairment charge from the revaluation of intangible assets.
2. Reverse stock split to regain Nasdaq compliance. Effective January 2, 2026, Co-Diagnostics enacted a 1-for-30 reverse stock split. This corporate action was necessary to address the company's failure to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting. While the company regained compliance on March 9, 2026, the need for such a drastic measure indicated significant underlying financial distress and severely impacted investor confidence, with an ongoing risk of delisting if the share price falls below $1.00 again.
Show more
Stock Movement Drivers
Fundamental Drivers
The -67.6% change in CODX stock from 12/31/2025 to 4/21/2026 was primarily driven by a -60.5% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.06 | 1.64 | -67.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 22.6% |
| P/S Multiple | 12.6 | 5.0 | -60.5% |
| Shares Outstanding (Mil) | 1 | 2 | -33.0% |
| Cumulative Contribution | -67.6% |
Market Drivers
12/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CODX | -67.6% | |
| Market (SPY) | -5.4% | -3.5% |
| Sector (XLV) | -5.7% | 9.5% |
Fundamental Drivers
The -84.1% change in CODX stock from 9/30/2025 to 4/21/2026 was primarily driven by a -56.3% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.32 | 1.64 | -84.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | -38.0% |
| P/S Multiple | 11.3 | 5.0 | -56.3% |
| Shares Outstanding (Mil) | 1 | 2 | -41.4% |
| Cumulative Contribution | -84.1% |
Market Drivers
9/30/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CODX | -84.1% | |
| Market (SPY) | -2.9% | 0.6% |
| Sector (XLV) | 5.3% | -0.2% |
Fundamental Drivers
The -82.3% change in CODX stock from 3/31/2025 to 4/21/2026 was primarily driven by a -83.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.29 | 1.64 | -82.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 1 | -83.2% |
| P/S Multiple | 2.6 | 5.0 | 92.1% |
| Shares Outstanding (Mil) | 1 | 2 | -45.4% |
| Cumulative Contribution | -82.3% |
Market Drivers
3/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CODX | -82.3% | |
| Market (SPY) | 16.3% | 0.5% |
| Sector (XLV) | 1.3% | 0.4% |
Fundamental Drivers
The -96.3% change in CODX stock from 3/31/2023 to 4/21/2026 was primarily driven by a -98.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 44.40 | 1.64 | -96.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 1 | -98.2% |
| P/S Multiple | 1.3 | 5.0 | 287.8% |
| Shares Outstanding (Mil) | 1 | 2 | -47.6% |
| Cumulative Contribution | -96.3% |
Market Drivers
3/31/2023 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CODX | -96.3% | |
| Market (SPY) | 63.3% | 1.1% |
| Sector (XLV) | 18.0% | 0.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CODX Return | -4% | -72% | -47% | -44% | -78% | -67% | -99% |
| Peers Return | 27% | -14% | -4% | 2% | 6% | -11% | 1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| CODX Win Rate | 50% | 42% | 50% | 25% | 50% | 0% | |
| Peers Win Rate | 65% | 45% | 48% | 50% | 57% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CODX Max Drawdown | -23% | -74% | -60% | -47% | -99% | -73% | |
| Peers Max Drawdown | -8% | -27% | -20% | -5% | -18% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DHR, ABT, TMO, HOLX, QGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/21/2026 (YTD)
How Low Can It Go
| Event | CODX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.8% | -25.4% |
| % Gain to Breakeven | 1821.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -73.2% | -33.9% |
| % Gain to Breakeven | 273.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -89.4% | -19.8% |
| % Gain to Breakeven | 843.8% | 24.7% |
| Time to Breakeven | 247 days | 120 days |
Compare to DHR, ABT, TMO, HOLX, QGEN
In The Past
Co-Diagnostics's stock fell -94.8% during the 2022 Inflation Shock from a high on 2/9/2021. A -94.8% loss requires a 1821.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Co-Diagnostics (CODX)
AI Analysis | Feedback
Here are 1-3 brief analogies for Co-Diagnostics (CODX):- They're like the Intel for the molecular diagnostics industry, providing the essential 'processors' (reagents) that power disease detection tests.
- Think of them as a focused Abbott Laboratories for PCR-based diagnostic tests, developing kits for everything from COVID-19 to mosquito-borne illnesses, and even portable testing devices.
- They are like a Carvana for lab-quality diagnostic tests, aiming to make sophisticated molecular testing (like PCR) more accessible, even at point-of-care or at home.
AI Analysis | Feedback
```html- PCR Diagnostic Reagents: These are core components developed, manufactured, and sold for diagnostic tests that detect and analyze nucleic acid molecules.
- PCR Diagnostic Tests: A variety of diagnostic tests for infectious diseases including COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus.
- Multiplexed Mosquito Tests: Three specific tests designed to identify diseases carried by mosquitos.
- Molecular Tools: Products for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications, including identifying genetic traits in plant and animal genomes.
- Portable PCR Device: A device designed to bring PCR testing capabilities to patients in point-of-care and at-home settings.
- Integrated Lab Systems: Self-contained laboratory systems comprising diagnostic equipment from other manufacturers, intended for resale.
AI Analysis | Feedback
Co-Diagnostics, Inc. (CODX) primarily sells its molecular diagnostics products, reagents, and testing equipment to other companies and organizations, rather than directly to individuals. While specific major customer names are not publicly disclosed in the provided background information (and are generally not made public by companies in this industry unless a customer represents a significant portion of revenue), Co-Diagnostics' clientele can be categorized based on its product offerings and target applications:
- Clinical and Diagnostic Laboratories: This broad category includes hospitals, independent diagnostic laboratories, and various point-of-care settings. These customers utilize Co-Diagnostics' PCR diagnostic tests (e.g., for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus), reagents, molecular tools for infectious disease detection, and liquid biopsy solutions for cancer screening. They also serve as potential users for the portable PCR device.
- Public Health Organizations and Government Agencies: These entities are major customers for large-scale testing programs, disease surveillance (e.g., for mosquito-borne viruses like dengue, chikungunya, and zika), and public health initiatives, particularly concerning infectious disease outbreaks and environmental monitoring.
- Agricultural and Veterinary Sector: Companies and institutions in this sector purchase tests for identifying genetic traits in plant and animal genomes, supporting applications in agriculture, animal health, and breeding programs.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dwight H. Egan, Chief Executive Officer, Co-President and Chairman of the Board
Mr. Egan is a co-founder of Co-Diagnostics, Inc., and has served as an officer and director since April 2013. He has been involved in private investment since February 1999. Previously, he was a senior executive at Data Broadcasting Corporation from 1995 to 1999, a provider of wireless, real-time financial market data. Mr. Egan also co-founded Broadcast International, Inc. in 1984, serving as its CEO and Chairman of the Board until its acquisition by Data Broadcasting Corporation in 1995, which led to the creation of CBS MarketWatch, a financial news site that underwent an initial public offering. His experience includes directing a public company and working with capital markets.
Brian L. Brown, CPA, Chief Financial Officer, Secretary and Principal Accounting Officer
Mr. Brown was appointed Chief Financial Officer in February 2021. Prior to joining Co-Diagnostics, he served as CFO of A-Core Concrete Cutting, Inc., a privately held specialty construction company. He also held roles as Vice President of Accounting, Treasury & Investor Relations, and Director of Finance for Sportsman's Warehouse Holdings, Inc. (Nasdaq: SPWH), a publicly traded outdoor sporting goods retailer, for over 10 years. Mr. Brown is a licensed CPA in Utah and holds both a Master of Professional Accountancy and a Bachelor of Arts in Accounting from the University of Utah. His responsibilities have included SEC reporting, internal controls, audits, mergers and acquisitions, and financial forecasting.
Richard Abbott, President
Mr. Abbott was appointed President of Co-Diagnostics, Inc. in March 2024. Before this role, he served as President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021, where he was instrumental in establishing the teams and technology for the Co-Dx PCR platform. With over 25 years of experience in senior leadership positions within in-vitro diagnostics companies, Mr. Abbott's background includes serving as VP of Engineering at BioFire Diagnostics, where he led cross-functional teams that generated billions of dollars in revenue. He holds a Master of Science degree from Brigham Young University and an M.B.A. from the Wharton Business School.
Seth Egan, Chief Commercialization Officer
Mr. Egan is a co-founder of Co-Diagnostics, Inc. and has spearheaded the company's sales, marketing, and product commercialization efforts since its inception. He has been pivotal in executive management, including company operations, financings, product introductions, and managing the Co-Dx/CoSara joint venture relationship in India. His leadership has contributed to the sale of approximately 35 million Logix Smart® tests globally. Mr. Egan earned a Bachelor of Science in Business Communications from Utah Valley University.
Christopher Thurston, Chief Technology Officer and AI Officer
Mr. Thurston was appointed Chief Technology Officer in March 2024. He has a history of developing software platforms for companies such as Ernst and Young and BioMerieux. As a co-inventor of the Co-Dx PCR platform at Idaho Molecular, which was acquired by Co-Dx in 2021, he now leads the company's newly formed artificial intelligence business unit. In this role, Mr. Thurston is responsible for integrating proprietary AI applications into the Co-Dx™ Primer Ai™ platform.
AI Analysis | Feedback
Key Risks to Co-Diagnostics (CODX)
- Financial Viability Due to Significant Revenue Decline and High Cash Burn: Co-Diagnostics has experienced a drastic reduction in revenue following the maturation of the COVID-19 testing market. For example, Q3 2025 revenue was only $0.1 million, a substantial decline from previous periods. The company is operating at a significant net loss, which was $5.9 million in Q3 2025. This situation is unsustainable without constant financing, as operating expenses vastly exceed current revenue. The company's limited cash and marketable securities, which stood at $11.4 million as of September 30, 2025, provide a very short cash runway, sufficient for only a few quarters of operation.
- Regulatory Challenges and Delays in Commercializing New Diagnostic Platforms: A critical risk stems from delays in obtaining regulatory approvals, particularly for its Co-Dx PCR platform (including the Co-Dx PCR Home™ and Co-Dx PCR Pro™). The entire platform remains under regulatory review and is not yet available for sale, pushing back crucial revenue-generating commercialization timelines. Management's target for commercialization in mid-2026 is highly contingent on successful and timely resubmission to regulatory bodies like the U.S. Food and Drug Administration (FDA). A prior US FDA submission withdrawal in February 2025 underscores the challenges in this area.
- Market Dependence and Intense Competition Post-COVID-19 Pandemic: Co-Diagnostics' revenue was heavily reliant on its COVID-19 diagnostic kits, and the decline in demand for these tests has significantly impacted its financial performance. The company is currently undergoing a "post-pandemic platform pivot" to develop and commercialize new multiplex tests for point-of-care use. However, the molecular diagnostics market is intensely competitive, and successfully establishing a strong position with its new pipeline, while also navigating customer demands for comprehensive solutions, presents a significant ongoing challenge.
AI Analysis | Feedback
null
AI Analysis | Feedback
Co-Diagnostics (NASDAQ: CODX) operates within several significant addressable markets for its molecular diagnostic products and services.
- Infectious Disease Molecular Diagnostics Market (Global): The global infectious disease molecular diagnostics market size was calculated at approximately USD 46.03 billion in 2024 and is expected to reach around USD 63.37 billion by 2034. This market encompasses a broad range of molecular tests for infectious agents, including many of the diseases Co-Diagnostics targets. The Polymerase Chain Reaction (PCR) segment accounted for the largest revenue share in 2024 within this market.
- PCR Molecular Diagnostics Market (Global): The global PCR molecular diagnostics market size was valued at USD 8.67 billion in 2024 and is projected to grow to USD 14.28 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 5.7%. Another estimate places the global PCR market at USD 10.75 billion in 2025, growing to USD 22.81 billion by 2034.
- COVID-19 Diagnostic Tests Market (Global): The global COVID-19 diagnostics market size reached USD 58.3 billion in 2024. However, it is projected to decline to USD 29.0 billion by 2033.
- Tuberculosis Diagnostic Tests Market (Global): The global tuberculosis diagnostics test market size was estimated at USD 2.4 billion in 2024 and is expected to grow to USD 4.1 billion by 2034. In North America, this market stood at USD 0.62 billion in 2023, with the U.S. market projected to reach USD 0.67 billion by 2026.
- Hepatitis B and C Diagnostic Tests Market (Global): The global hepatitis diagnostic tests market size was valued at USD 3.82 billion in 2023 and is expected to reach USD 5.90 billion by 2030. The North America hepatitis diagnostic tests market dominated in 2023 with a revenue share of 42.7%.
- Human Papillomavirus (HPV) Testing Market (Global): The global HPV testing market size is anticipated to rise from US$ 1,400 million in 2025 to US$ 2,816.3 million by 2032. For the combined HPV testing and Pap test market, the global size was valued at USD 4.7 billion in 2025, projected to reach USD 7.2 billion by 2034. North America is the largest market, accounting for approximately 50% of the global share for HPV testing.
- Malaria Diagnostics Market (Global): The global malaria diagnostics market size was valued at around USD 819.1 million in 2023 and is estimated to grow at a 5% CAGR from 2024 to 2032. The U.S. malaria diagnostics market size reached USD 303.1 million in 2023.
- Mosquito-borne Infections Testing Market (Global): The global mosquito-borne infections testing market size was calculated at USD 27.11 billion in 2024 and is predicted to increase to approximately USD 39.52 billion by 2034. This market includes tests for diseases such as dengue, malaria, and Zika virus.
- Liquid Biopsy Market for Cancer Screening (Global): The global liquid biopsy market size was estimated at USD 7.05 billion in 2025 and is predicted to rise to USD 22.69 billion by 2034. North America accounted for the largest market share of 45.59% in 2024. The U.S. liquid biopsy market is projected to rise from US$ 2.78 billion in 2026 to US$ 8.90 billion by 2035.
- Point-of-Care (POC) Molecular Diagnostics Market / Portable PCR Devices (Global): The global point-of-care molecular diagnostics market size was calculated at US$ 4.05 billion in 2024, growing to US$ 4.48 billion in 2025, and is projected to reach around US$ 11.03 billion by 2034. North America held approximately a 40-45% share in the global point-of-care molecular diagnostics market in 2024.
- Agricultural Applications (Molecular Tools): null
AI Analysis | Feedback
Co-Diagnostics (CODX) anticipates several key drivers for future revenue growth over the next 2-3 years:- Launch and Commercialization of the Co-Dx PCR Point-of-Care Platform and New Diagnostic Tests: Co-Diagnostics is actively focused on bringing its proprietary Co-Dx PCR platform to the point-of-care market. This includes a robust pipeline of diagnostic tests for critical indications such as Tuberculosis (TB), an enhanced COVID-19 test, a 4-plex respiratory panel (influenza A/B, COVID-19, RSV), and an 8-plex Human Papillomavirus (HPV) panel. Clinical evaluations for these tests commenced in 2025, with commercialization in target markets anticipated as early as mid-2026, pending necessary regulatory approvals from bodies like the U.S. FDA, SAHPRA in South Africa, and CDSCO in India. The company believes its platform can revolutionize infectious disease testing by making it more affordable, accessible, and decentralized.
- Geographic Market Expansion: The company is strategically expanding its presence in international markets, with a particular focus on India and South Africa. India is identified as a top priority for TB testing, with plans for regulatory submissions and leveraging the existing footprint of its joint venture, CoSara Diagnostics, for manufacturing and commercialization. CoSara has already received a CDSCO license to manufacture and sell the CoSara PCR Pro™ Instrument in India and obtained ISO 13485 certification. Additionally, Co-Diagnostics has secured patents for its Co-Dx PCR platform technologies in Japan and Australia, further strengthening its international intellectual property protection and supporting global market expansion. The Middle East market is also being targeted for respiratory infectious disease diagnostics.
- Increased Adoption of Decentralized Point-of-Care and At-Home Diagnostic Testing: Co-Diagnostics is positioned to capitalize on the growing market trend towards decentralized diagnostic solutions, including point-of-care and at-home testing. The Co-Dx PCR platform is specifically designed to deliver gold-standard PCR accuracy in compact, user-friendly devices suitable for near-patient environments. The rising patient preference for rapid and convenient testing in settings like physician offices is projected to fuel significant growth in the respiratory infectious disease diagnostics market, which the Co-Dx platform addresses.
AI Analysis | Feedback
Share Repurchases
- Co-Diagnostics authorized a share repurchase program of up to $30.0 million in March 2022.
- By June 30, 2025, the company completed repurchases totaling approximately $15.58 million for 4,848,678 shares under the program.
Share Issuance
- Between December 31, 2024, and September 30, 2025, Co-Diagnostics issued approximately 15 million shares.
- Following the third quarter of 2025, a Registered Direct Offering (RDO) generated approximately $7.0 million in gross proceeds.
- A 1-for-30 reverse stock split was implemented effective January 2, 2026, to regain Nasdaq compliance and reduce the number of outstanding shares.
Inbound Investments
- In 2023, the company received approximately $12.6 million in grant funding to support regulatory and clinical validation activities for its tuberculosis (TB) test, upper respiratory multiplex panel, and human papillomavirus (HPV) test development.
Outbound Investments
- In the third quarter of 2025, Co-Diagnostics formed CoMira Diagnostics, a joint venture with Arabian Eagle Manufacturing, to commercialize Co-Dx technologies and intellectual property across KSA and 18 MENA nations.
- The company engaged Maxim Group LLC in Q3 2025 to explore a potential strategic transaction, including a SPAC transaction, for its existing joint venture in India, CoSara Diagnostics.
Capital Expenditures
- In 2024, Co-Diagnostics inaugurated a new manufacturing facility in South Salt Lake, dedicated to producing Co-Primers oligonucleotides, the Co-Dx PCR Pro instrument, and test cups for the new Co-Dx PCR platform.
- Capital expenditures totaled approximately $641,065 over the 12 months ending February 2023.
- The company is prioritizing its capital towards the advancement and commercialization of its Co-Dx PCR platform and associated diagnostic tests.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Co-Diagnostics Earnings Notes | 12/16/2025 | |
| Day 6 of Loss Streak for Co-Diagnostics Stock with -70% Return (vs. -49% YTD) [11/4/2025] | 11/05/2025 | |
| Can Co-Diagnostics Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CODX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 92.72 |
| Mkt Cap | 137.7 |
| Rev LTM | 24,778 |
| Op Inc LTM | 4,760 |
| FCF LTM | 5,291 |
| FCF 3Y Avg | 5,247 |
| CFO LTM | 6,439 |
| CFO 3Y Avg | 6,548 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.0% |
| Rev Chg 3Y Avg | -0.2% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 18.0% |
| Op Inc Chg 3Y Avg | -1.1% |
| Op Mgn LTM | 18.2% |
| Op Mgn 3Y Avg | 17.8% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 21.6% |
| CFO/Rev 3Y Avg | 20.0% |
| FCF/Rev LTM | 16.7% |
| FCF/Rev 3Y Avg | 15.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 137.7 |
| P/S | 4.4 |
| P/Op Inc | 20.0 |
| P/EBIT | 18.0 |
| P/E | 24.7 |
| P/CFO | 16.9 |
| Total Yield | 3.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.4% |
| 3M Rtn | -23.0% |
| 6M Rtn | -17.5% |
| 12M Rtn | -0.6% |
| 3Y Rtn | -11.8% |
| 1M Excs Rtn | -8.1% |
| 3M Excs Rtn | -26.9% |
| 6M Excs Rtn | -23.1% |
| 12M Excs Rtn | -34.9% |
| 3Y Excs Rtn | -81.7% |
Price Behavior
| Market Price | $1.64 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/12/2017 | |
| Distance from 52W High | -95.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.14 | $7.25 |
| DMA Trend | down | down |
| Distance from DMA | -23.2% | -77.4% |
| 3M | 1YR | |
| Volatility | 234.1% | 2,294.2% |
| Downside Capture | 0.30 | 1.66 |
| Upside Capture | -361.50 | 14.38 |
| Correlation (SPY) | -2.7% | 0.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.05 | -0.07 | -2.05 | 1.38 | 0.60 | 0.93 |
| Up Beta | -3.93 | -2.63 | -2.19 | 16.78 | 2.27 | 1.96 |
| Down Beta | 18.38 | 10.19 | 113.44 | 57.37 | 14.93 | 8.58 |
| Up Capture | -706% | -310% | -241% | -33% | 35% | 23% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 15 | 25 | 49 | 110 | 317 |
| Down Capture | -299% | -76% | -6999% | 244% | 158% | 112% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 21 | 32 | 71 | 136 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CODX | |
|---|---|---|---|---|
| CODX | -84.4% | 2,289.6% | 1.01 | - |
| Sector ETF (XLV) | 9.2% | 16.0% | 0.37 | -0.0% |
| Equity (SPY) | 23.7% | 12.7% | 1.52 | -0.3% |
| Gold (GLD) | 41.4% | 27.5% | 1.25 | -1.2% |
| Commodities (DBC) | 22.4% | 16.2% | 1.25 | 4.3% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 1.9% |
| Bitcoin (BTCUSD) | -10.4% | 42.7% | -0.14 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CODX | |
|---|---|---|---|---|
| CODX | -64.3% | 1,026.5% | 0.41 | - |
| Sector ETF (XLV) | 5.9% | 14.6% | 0.22 | 1.3% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 1.8% |
| Gold (GLD) | 21.6% | 17.8% | 0.99 | -0.4% |
| Commodities (DBC) | 10.9% | 18.8% | 0.47 | 2.0% |
| Real Estate (VNQ) | 4.1% | 18.8% | 0.12 | 2.1% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 2.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CODX | |
|---|---|---|---|---|
| CODX | -37.3% | 784.2% | 0.37 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.47 | 0.4% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 0.5% |
| Gold (GLD) | 13.7% | 15.9% | 0.71 | 0.6% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 1.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 0.7% |
| Bitcoin (BTCUSD) | 68.0% | 66.9% | 1.07 | 1.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2026 | -12.9% | -25.3% | |
| 11/13/2025 | -10.9% | -13.4% | -33.8% |
| 8/14/2025 | 10.9% | 15.6% | 33.2% |
| 3/27/2025 | -18.3% | -17.5% | -5.2% |
| 11/7/2024 | -3.4% | -6.8% | -27.7% |
| 8/8/2024 | 9.8% | 21.6% | 25.5% |
| 3/14/2024 | -10.1% | -1.7% | -0.6% |
| 11/9/2023 | -10.2% | 9.8% | -8.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 7 | 4 |
| # Negative | 13 | 11 | 13 |
| Median Positive | 9.6% | 5.1% | 14.6% |
| Median Negative | -12.2% | -17.5% | -21.5% |
| Max Positive | 10.9% | 21.6% | 33.2% |
| Max Negative | -30.7% | -51.0% | -48.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.